# Safety of CHIR-258 (TKI258) in Advanced Solid Tumors

> **NCT01270906** · PHASE1 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 35 (actual)

## Conditions studied

- Neoplasms
- Cancer
- Tumors

## Interventions

- **DRUG:** CHIR-258 (TKI258)

## Key facts

- **NCT ID:** NCT01270906
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2003-12
- **Primary completion:** 2006-10
- **Final completion:** —
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2011-01-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01270906

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01270906, "Safety of CHIR-258 (TKI258) in Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01270906. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*